anti-BCMA, BCMA CAR-T, chimeric antigen receptor T cell therapy, China, Immune thrombocytopenia, ITP
Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)
March 2023: Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therapies. However, the other part o..